PharmaCyte Biotech Inc (PMCB)

[1234jklm]

CiaB technology to treat Pancreatic Cancer ( from Austrianova's website ) Cancer
Chemotherapeutic agents have a long history of use in the clinic for a variety of cancer. However, the major drawback to their use are the side effects from generally toxicity in the body due to the need for activation in the liver. These side effects limit the dosing of the chemotherapy. We have developed Cell-in-a-Box™, as a means to a create a novel, tumor local site of chemotherapeutic activation. This allows lower doses of chemotherapeutic to be given with enhanced, improved and targeted anti-tumor activity but importantly without the side effects of classical chemotherapy. Safety and efficacy has been demonstrated and published in clinical trials to treat pancreatic cancer. These trials showed a 2 time better median survival of patients. Later stage clinical trials with additional treatments included are now planned and will be performed by our partner, PharmaCyte Biotech. A similar approach has been shown to work in dogs with spontaneously occurring mammary (breast) cancer. This kind of strategy can be used to treat almost all kind of cancer. Moreover, other cancer therapy molecules such as monoclonal antibodies, cell growth inhibitors, anti-angiogenic factors etc can be produced from Cell-in-a-Box™ encapsulated cells.
Advantages of encapsulated cell mediated low dose chemotherapy include:

Less or no side effects of treatment
More effective anti-tumor effect due to targeted and localised treatment
Allows combination chemotherapy regimes